The difference between ibrutinib/ibrutinib and zanubrutinib

Ibrutinib/ Ibrutinib and zanubrutinib are both drugs used to treat certain types of leukemia and lymphoma, but there are some key differences between them.

First of all, from the perspective of indications, ibrutinib is widely used to treat multiple types of leukemias and lymphomas, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoid follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), etc. Zanubrutinib is mainly used to treat certain types of lymphoma, such as mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL), and adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Secondly, from the mechanism of action, ibrutinib mainly prevents the growth and activation of abnormal cells by inhibiting Bruton's tyrosine kinase (BTK) in theB cell receptor signaling pathway. Zanubrutinib is a small molecule inhibitor of Bruton's tyrosine kinase, which works by inhibiting another tyrosine kinase, ZAP-70.

Finally, from the perspective of administration, ibrutinib is usually given to patients in the form of an oral medication, taken once a day or as directed by the doctor. Zanubrutinib, on the other hand, is given to patients as an intravenous injection, usually by a medical professional in a medical setting.

In general, there are obvious differences between ibrutinib and zanubrutinib in indications, mechanism of action, and mode of administration. When choosing which drug to use, a comprehensive consideration should be based on the patient's specific illness, physical condition, and doctor's recommendations. At the same time, both drugs have certain side effects and risks, so you should strictly follow the doctor's instructions when using them, and pay close attention to the patient's reaction and condition changes.